Tested treatment plan for locally advanced rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 study looks at a modified “sandwich” treatment sequence for people with locally advanced rectal cancer—aiming to control the cancer before and after surgery. It may help you if you’re eligible and can follow the study’s treatment and safety requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed rectal adenocarcinoma (a specific type of rectal cancer).
- Your cancer stage fits T3–T4 or T any with lymph node spread, and your team expects it can be fully removed with surgery (R0 resection).
- There is no spread to distant organs (no metastasis).
- You do not currently have an intestinal blockage; if you had one, it must be relieved after a proximal colostomy.
- You are between 18 and 75 years old.
- You have not had any prior radiation, surgery, or chemotherapy for this cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a very low dose of radiation to a combination of immunotherapy (pucotenlimab) and chemotherapy (CAPEOX) can help shrink rectal cancer tumors that have not spread. It is for people with locally advanced rectal cancer that is pMMR (meaning the cancer cells have normal DNA repair).
This trial tests a new combination for rectal cancer that hasn't spread far: a short course of radiation followed by two drugs (AK112 and CAPOX). The goal is to shrink the tumor before surgery and possibly avoid more aggressive treatments.
This Phase 3 study compares giving chemotherapy before rectal surgery versus giving it after surgery, using a tailored plan based on your risk. The goal is to see which timing helps more people with locally advanced rectal cancer stay cancer-free and live longer.
This trial tests whether adding the immunotherapy drug dostarlimab (a checkpoint inhibitor) to standard chemotherapy (XELOX) after chemoradiation improves outcomes for patients with locally advanced rectal cancer that is not MSI-high. You may be eligible if your tumor has specific genetic features called pMMR/MSS or MSI-low, and you have not received prior chemotherapy or radiation.
This trial tests whether adding two types of immunotherapy (cemiplimab with either fianlimab or REGN7075) to standard chemotherapy is safe and effective for people with locally advanced rectal cancer that has not been treated before. It may help shrink the tumor enough to allow surgery that preserves the ability to control bowel movements.
This Phase 1 study tests a “smart” total treatment plan using chemotherapy (chemo) and radiation before surgery for people with locally advanced rectal cancer. The goal is to see if this approach is safe and can work well while helping plan treatment based on your situation.
Hear when a new Advanced Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.